Infusion of ILC2 cells that are substantially free of ILC3 and MPP2 cells can be used to treat steroid refractory GvHd. Gastrointestinal tract graft-versus-host disease (GvHD) is relatively common following allogeneic stem cell transplantation however the prognosis is poor for steroid-refractory GvHD due to lack of alternate treatments. Ex vivo expansion and infusion of mouse ILC2 cells at key timepoints have diminished GvHD and provide encouraging results.
• New treatment for steroid-refractory GvHD
• Purified ILC2 cells are free of contaminating MPP2 and ILC3 cells
• Infusion can be from donor or recipient cells
- Type 2 Innate Lymphoid Cells Treat and Prevent Acute Gastrointestinal Graft-Versus-Host Disease J Clin Invest. 2017 May 1;127(5):1813-1825.